10,563 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Entropy Technologies LP

Entropy Technologies LP purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 10,563 shares of the life sciences company’s stock, valued at approximately $1,378,000.

A number of other institutional investors also recently added to or reduced their stakes in ILMN. Janney Montgomery Scott LLC boosted its position in Illumina by 41.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 3,070 shares of the life sciences company’s stock worth $422,000 after acquiring an additional 900 shares during the period. Empowered Funds LLC boosted its position in shares of Illumina by 26.9% in the 1st quarter. Empowered Funds LLC now owns 3,340 shares of the life sciences company’s stock valued at $459,000 after purchasing an additional 708 shares during the period. Concurrent Investment Advisors LLC acquired a new position in shares of Illumina in the 1st quarter valued at $307,000. Sei Investments Co. boosted its position in shares of Illumina by 309.3% in the 1st quarter. Sei Investments Co. now owns 71,143 shares of the life sciences company’s stock valued at $9,769,000 after purchasing an additional 53,761 shares during the period. Finally, QRG Capital Management Inc. boosted its position in Illumina by 25.4% during the 1st quarter. QRG Capital Management Inc. now owns 6,874 shares of the life sciences company’s stock worth $944,000 after acquiring an additional 1,393 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on ILMN shares. Piper Sandler decreased their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research report on Monday. StockNews.com started coverage on Illumina in a research note on Thursday, August 29th. They set a “buy” rating for the company. Daiwa America raised Illumina to a “strong-buy” rating in a report on Friday, August 16th. Leerink Partners raised their target price on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, TD Cowen raised their target price on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Trading Down 1.0 %

Shares of NASDAQ:ILMN opened at $146.17 on Thursday. The company has a market capitalization of $23.18 billion, a P/E ratio of -14.68 and a beta of 1.13. Illumina, Inc. has a 1 year low of $92.69 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The business’s 50 day simple moving average is $138.84 and its 200 day simple moving average is $123.95.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.33 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.